Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Miebo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 22, 2024
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Miebo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 04, 2024
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate Early Treatment Outcomes With Mieboâ„¢ in Subjects With Dry Eye Disease
Details : Undisclosed
Product Name : Miebo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 13, 2024
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bausch + Lomb Launches MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) in the United States
Details : MIEBO (perfluorohexyloctane ophthalmic solution) is used for the treatment of the signs and symptoms of dry eye disease (DED). MIEBO is the first and only prescription eye drop approved for DED that directly targets tear evaporation.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 09, 2023
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : SENJU PHARMACEUTICAL CO LTD
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Senju acquires Japan rights to develop, manufacture, and commercialize NOV03 (perfluorohexyloctane ophthalmic solution), the first and only prescription treatment for signs and symptoms of dry eye disease that directly targets tear e...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 13, 2023
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : SENJU PHARMACEUTICAL CO LTD
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Novaliq
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Miebo (perfluorohexyloctane) is the first drug approved by USFDA to treat dry eye disease associated with Meibomian gland dysfunction. It stabilizes the lipid layer for hours to protect the tear film and has the ability to penetrate the Meibomian glands.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 18, 2023
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Novaliq
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Novaliq
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NOV03 (Perfluorohexyloctane) is the first drug developed to treat dry eye disease associated with Meibomian gland dysfunction in a highly effective way. It stabilizes the lipid layer for hours to protect the tear film and has the ability to penetrate the...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2023
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Novaliq
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of NOV03 on the Tear Film
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 13, 2023
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Novaliq
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NOV03 (perfluorohexyloctane) Ophthalmic Soluton, is an investigational, proprietary, water-free, single-component preservative-free eye drop , an investigational treatment with a proposed indication of treating the signs and symptoms of dry eye disease.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 07, 2022
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Novaliq
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Novaliq
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NOV03 (perfluorohexyloctane) A potential first-in-class eye drop with a novel mechanism of action, NOV03 is an investigational therapy to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD).
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 09, 2022
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Novaliq
Deal Size : Inapplicable
Deal Type : Inapplicable